Hongwu Zheng, PhD

Highlights

45

1 grant

PI
Identifying molecular vulnerabilities of ALT-dependent cancers
National Cancer Institute · 2024–2029
R01CA276349-03

Completed grants (2)

Co-I
Targeting molecular vulnerability of ATRX mutant gliomas (YR2 Renewal)
William Rhodes Center for Glioblastoma - Collaborative Research Initiative · 2022–2022
WRC 223372-01
Co-I
Targeting Molecular Vulnerabilities of ATRX Mutant Gliomas
William Rhodes Center for Glioblastoma - Collaborative Research Initiative · 2020–2021
WRC 205030-01

A Promising Solution to a Cancer Drug Resistance Problem
August 3, 2026
A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine.
Discovery Suggests New Way to Target Mantle Cell Lymphoma
November 22, 2022
A form of blood cancer known as mantle cell lymphoma is critically dependent on a protein that coordinates gene expression, such that blocking its activity with an experimental drug dramatically slows the growth of this lymphoma in preclinical tests, according to a study from Weill Cornell Medicine researchers.